XTL Biopharmaceuticals Sign License Agreement with Yeda Research to Develop hCDR1 Treatment for SLE
January 08, 2014 at 08:05 AM EST
XTL Biopharmaceuticals (NASDAQ: XTLB ) today announced it has signed a licensing agreement with Yeda Research and Development Company Ltd. ("Yeda") to develop hCDR1, a Phase II-ready asset for the treatment of Systemic Lupus Erythematosus (SLE). See full press release (c) 2014 Benzinga.com. Benzinga does not
